Expertise

no-image

Health Strategies Insights Team

Health Strategies Insights by EVERSANA gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market access questions.

Health Strategies Insights by EVERSANA gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market access questions.

Learn More About Health Strategies Insights.

Articles by Health Strategies Insights Team

white paper-insights
COVID-19’s Impact on Brand Access

The current public health pandemic is impacting healthcare stakeholders from doctors and nurses in the frontlines to payers and PBMs. EVERSANA™ is monitoring the constant changes to access and benefit consideration, tracking payer responses, and key trends that may impact your brand access strategy. According to recent research released by Health Strategies Insights by EVERSANA™, […]

white paper-insights
Brand Access Marketplace Dynamics: Respiratory

This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective identification of opportunities and risks for Respiratory brands. Get answers to key questions such as: What level of influence […]

white paper-insights
Brand Access Marketplace Dynamics: Multiple Sclerosis

This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective identification of opportunities and risks for Multiple Sclerosis brands. Get answers to key questions such as: What level of […]

white paper-insights
Brand Access Marketplace Dynamics: HIV

This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective identification of opportunities and risks for HIV brands. Get answers to key questions such as: What level of influence […]

white paper-insights
Brand Access Marketplace Dynamics: Autoimmune

This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective identification of opportunities and risks for Autoimmune brands. Get answers to key questions such as: What level of influence […]

ACCESSEXPRESS® by EVERSANA Payer Coverage and Reimbursement Case Study

ACCESSEXPRESS allows you to have full control of the survey process getting answers to your most pressing business questions within hours. See how our client used our research platform to assess payer coverage and reimbursement for an upcoming indication expansion. Learn more about ACCESSEXPRESS® by EVERSANA! Fill out the form below to download the Case […]

Oncology Market: Outlook of Brand Access and Insights

The oncology market is constantly changing and EVERSANA continues to assess current and future market trends, payer willingness to pay and the optimal patient support services to ensure you have all the insights you need to answer your most critical business questions. In this summary, our Health Strategies Insights team provides highlights from multiple reports […]

Validate and Inform your Account Access Strategies and Tactics

With $250 million in product revenue, our client is the U.S. subsidiary of a European niche biopharmaceutical company looking to build its presence in the U.S. marketplace in anticipation of future product launches. See how the Health Strategies Insights by EVERSANA Team helped the client put an  account strategy in place for each key payer […]

Autoimmune Patient Services Best Practices

Autoimmune Patient Services Best Practices provides highlights from an annual report, available in conjunction with a live, interactive database, updated quarterly which helps to identify patient services best practices by users (e.g., prescribers, office staff and patients) which gives insights into the most valued and highest rated patient services for brands across the autoimmune market. […]

Improving the Impact of an Oncology Patient Access Program

Our client, a specialty pharmaceutical company focused on the research and development of new therapies in two high-cost complex drug categories, sought to benchmark its patient assistance program against those of its competitors in order to improve relationships within target oncologists’ offices. The Challenge The client needed to assess the image of its patient assistance […]

U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines

According to a recent study from Health Strategies Insights by EVERSANA, 89% of U.S. physicians disagree with Germany’s determinations of the clinical benefit of innovative diabetes medicines. Learn more about our Market Access products & capabilities! Contact us with your questions and data needs, and an expert will follow up shortly.

What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.

Earlier in the month, the Institute for Clinical and Economic Review (ICER) issued a call for public input to help identify and prioritize non-drug topics for ICER assessments in 2020. It may seem like the ICER has always been focused on driving down the price of drugs, conducing health technology assessments to properly calculate the […]

Developing an Optimal Hub to Ensure Product Access

Prior to launching a new Hub, our client, a global biopharmaceutical company, needed to ensure that the services offered would be superior to those of other companies and ensure their product’s access in an increasingly competitive category. The Challenge Our client’s product was one of only a handful of FDA-approved products in a specific category. […]

Global Biosimilar Competitor Assessment – Who Wins in Biosimilar Access and Why?

The introduction of biosimilar products has created interesting changes in payer behavior across the global markets. For both innovator and biosimilar companies, it has been an effort to understand the demands of payers and succeed in what looked like a ‘winner-takes-all’ opportunity. As the first round of biosimilar introductions has passed, there are some interesting […]

German and United Kingdom Physicians Express Frustration with Health System Challenges

This brief by Health Strategies Insights summarizes preliminary results compiled from twelve 30-minute, one-on-one, in-depth, telephone interviews with a mix of physician specialists from the United Kingdom (U.K.) and Germany. While the physicians discussed benefits of their respective health care systems, many raised significant challenges and limitations in providing the care they believed would be […]

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in the access environment related to: • Current and emerging U.S. access trends • Response by stakeholders to market access […]

Insurance and Benefit Design

Insurance and Benefits Design provides insight on changes in insurance and benefit design in the next three years so you can anticipate the evolving access opportunities and risks for your company’s brands. Insurance and Benefit Design answers your questions about changes in the access environment related to: • Macrotrends • Benefit design and drug management […]

IDN Profiles

IDN Profiles provides insight on the size, structure, and business strategies of the leading IDNs so you can develop business and account plans. IDN Profiles answers your questions so you can develop business and account plans. Who are the leading IDNs? What are the organizational structure, payer mix, and strategic goals of each? How do […]

Macro Trends – Delivery Of Care

Delivery of Care provides insight on changes in delivery of care in the next three years so you can anticipate the evolving access opportunities and risks for your company’s brands. Delivery of Care answers your questions about changes in the access environment related to: Site-of-care shifts Transitions of care Technological advances in care delivery Care coordination […]

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in the access environment related to: • Current and emerging U.S. access trends • Response by stakeholders to market access […]

How Could Policy Changes to Protected Classes Impact Part D Access and Contracting?

(Content Updated 5/17) CMS Protected Class Rule Finalized, Slightly Loosened for Biopharma Following CMS’ 2018 proposed rule allowing for new protected class exceptions and a comment period for stakeholders through the beginning of this year, CMS has released a final rule addressing the Medicare Part D Protected Classes. The proposed rule allowed plans to restrict […]

biosimilar prioritization
Is your biosimilar product on the payer radar?

Biosimilars have been eagerly awaited in many European countries to realize cost savings from the biologics budget. Gaining insight on how European decision makers are currently prioritizing these biosimilars and how they expect this to shift by 2023 will allow a better understanding of the strategies that may prioritize revenue sources, identifying specific markets and […]

The Brink of the Biosimilar Revolution

Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020—if the price is right. Since the first biosimilar was approved in the United States in 2015, brand marketers have been bracing […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.